Abzena

Abzena is a leading biopharmaceutical CDMO+CRO specializing in the development and manufacturing of complex biologics, bioconjugates, and antibody-drug conjugates (ADCs). They offer a fully integrated suite of services spanning from early discovery through commercial product launch, working closely with their customers to de-risk and streamline development processes. Their expertise in bioconjugation, complex chemistry, and linker/payload design allows them to deliver high-quality and innovative solutions.

Abzena's global operations are centered around three state-of-the-art facilities in the UK and the USA, with locations in Cambridge, UK, Bristol, PA, and San Diego, CA. They are committed to scientific innovation, integrity, and quality, building collaborative partnerships with their clients and prioritizing the delivery of life-changing treatments to patients. Abzena's commitment to quality excellence is evident in their comprehensive quality programs and their dedication to meeting the highest standards in regulatory compliance.

Abzena offers flexible work arrangements, tailored to individual employee needs and roles. While specific details about the types of flexibility offered are not explicitly mentioned, the company’s commitment to creating an inclusive culture and empowering its employees suggests that they strive to accommodate diverse needs, including the potential for remote work, flexible schedules, or other arrangements.

Abzena offers a comprehensive Total Rewards program designed to meet the needs of employees and their families. Benefits vary by country and are based on local standards, but generally include robust health benefits, life and disability insurance, retirement schemes (401k in the US, workplace pension in the UK), paid time off for various reasons, education assistance, flexible work arrangements, and an employee referral program.

Abzena is a leading global biopharmaceutical CDMO+CRO specializing in the development and manufacture of complex biologics and bioconjugates, including antibody-drug conjugates (ADCs). Their mission is to accelerate the development and commercialization of novel treatments for patients by providing fully integrated, end-to-end solutions from early discovery through commercial product launch. They are committed to scientific innovation, quality excellence, and integrity in all their endeavors, working collaboratively with their partners to ensure the success of their drug programs.

Abzena fosters a culture of collaboration, integrity, and scientific innovation. They emphasize open communication, teamwork, and a commitment to delivering high-quality products and services, all with a focus on advancing new treatments for patients. They strive to create an inclusive environment where employees feel valued and empowered to contribute their unique perspectives.

Abzena is committed to building an inclusive culture that fosters, empowers, and celebrates the diverse voices of its employees, embracing their thoughts, experiences, and talents. They believe that a more inclusive company leads to better work, and they are dedicated to creating workplaces that reflect the communities they serve, so that everyone feels empowered. Their commitment extends to supporting and upholding fair and just practices and policies in all aspects of their operations.